FINANCIAL STATEMENTS CONSOLIDATED INCOME STATEMENT For the year ended 31 December 2017 9 months Year ended ended 31 December 31 December 2017 2016 Note m m Revenue 3 148.0 126.5 Cost of sales 57.2 41.9 Gross profit 90.8 84.6 Selling and marketing expenses 4.0 2.8 Research and development expenses 5 60.3 45.6 Corporate and administrative expenses 10.2 8.8 Other income 7 1.7 1.5 Operating profit before exceptional items and amortisation 18.0 28.9 Amortisation and impairment 8 109.7 64.0 Exceptional items 10 4.5 9.4 Operating loss 96.2 44.5 Share of movement of associates 11 3.4 0.4 Finance income 12 0.2 4.4 Finance expenses 12 2.8 0.4 Loss before taxation 102.2 40.1 Net taxation credit 13 16.5 8.0 Loss after taxation 85.7 32.1 Adjusted EBITDA 8 25.8 34.1 Loss per share Basic 14 12.6p 5.3p Diluted 14 12.6p 5.3p All results are attributable to shareholders of Vectura Group plc and are derived from continuing operations.
Adjusted EBITDA represents operating profit before exceptional items and amortisation, adding back share-based payments and depreciation.
Refer to note 8 Adjusted EBITDA.
Following the Skyepharma merger on 10 June 2016, the Group changed its accounting reference date to 31 December from 31 March.
Asa result, the comparative period presented is for the nine-months ended 31 December 2016 and only includes Skyepharmas results since the merger date.
To support a review of trends in performance, certain unaudited proforma information is within the Financial review.
The accompanying notes form an integral part of these consolidated financial statements.
Annual Report and Accounts 2017 Vectura Group plc 117
